IIPM - Admission Procedure
...we mean, should Ranbaxy fear No.13?
‘India Inc. going global’ no more sounds astounding! And why should it, when on one hand India Inc. is firing all
The acquisition is believed to have stemmed from Ranbaxy’s long term strategy of product portfolio expansion to garner a larger pie of the lucrative market of dermatology products. Renowned for its cost effective distribution channels, the acquisition is sure to propel Ranbaxy’s brand potential ahead, from the doldrums it seems to been in off late. It is estimated that the combined market value of the brands is close to $4.5 billion with sales hovering around $15 million.
However, Ranbaxy despite having paid a ‘lower than valued’ amount has to watch out as ‘all’ 13 brands come under the purlieu of ‘branded generic drugs’ – simply meaning that they either have already lost or will lose their patent shortly and then can be manufactured and marketed by all generic manufacturers. Hence, while the deal gives Ranbaxy a chance to get stronger in the dermatology drug market, it may have just placed its bet on a winning horse which has now gotten old! 4Ps
Edit bureau: Karan Mehrishi
For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2008
An IIPM and Professor Arindam Chaudhuri (Renowned Management Guru and Economist) Initiative
For More IIPM Info, Visit Below....
No comments:
Post a Comment